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Abstract: The noradrenaline and dopamine reuptake inhibitor bupropion is metabolized by CYP2B6
and recommended by the FDA as the only sensitive substrate for clinical CYP2B6 drug–drug in-
teraction (DDI) studies. The aim of this study was to build a whole-body physiologically based
pharmacokinetic (PBPK) model of bupropion including its DDI-relevant metabolites, and to qualify
the model using clinical drug–gene interaction (DGI) and DDI data. The model was built in PK-Sim®
applying clinical data of 67 studies. It incorporates CYP2B6-mediated hydroxylation of bupropion,
metabolism via CYP2C19 and 11β-HSD, as well as binding to pharmacological targets. The impact
of CYP2B6 polymorphisms is described for normal, poor, intermediate, and rapid metabolizers,
with various allele combinations of the genetic variants CYP2B6*1, *4, *5 and *6. DDI model per-
formance was evaluated by prediction of clinical studies with rifampicin (CYP2B6 and CYP2C19
inducer), fluvoxamine (CYP2C19 inhibitor) and voriconazole (CYP2B6 and CYP2C19 inhibitor).
Model performance quantification showed 20/20 DGI ratios of hydroxybupropion to bupropion
AUC ratios (DGI AUCHBup/Bup ratios), 12/13 DDI AUCHBup/Bup ratios, and 7/7 DDGI AUCHBup/Bup
ratios within 2-fold of observed values. The developed model is freely available in the Open Systems
Pharmacology model repository.
Keywords: physiologically based pharmacokinetic modeling; bupropion; hydroxybupropion;
cytochrome P450 2B6 (CYP2B6); drug-drug-interactions (DDIs); drug-gene-interactions (DGIs)
1. Introduction
Bupropion is used for the treatment of major depressive disorders and to support
smoking cessation [1]. Nearly one out of 10 prescriptions among psychotherapeutics was
attributed to bupropion in 2018 [2]. In the treatment of depressive disorders, it is either used
as monotherapy or in combination with other antidepressant agents, and is administered
as oral immediate release, sustained release or extended release tablets [1,3].
Bupropion and various of its metabolites are pharmacologically active [4].
Hydroxybupropion is one of the major metabolites and is formed by cytochrome P450 (CYP)
2B6-mediated hydroxylation of bupropion. Bupropion and hydroxybupropion are known
inhibitors of dopamine and noradrenaline reuptake transporters. Furthermore, they act as
antagonists to various acetylcholine receptors and serotonin reuptake transporters [5–7].
Erythrohydrobupropion and threohydrobupropion are further metabolites of bupropion
and formed via 11β-hydroxysteroid-dehydrogenase (11β-HSD) as the rate-limiting step
in the reaction pathway [8]. After administration of a single dose of 200 mg bupropion,
nearly 97% of total bupropion was recovered in urine (87%) and feces (10%).
However, only 0.5% of unchanged bupropion was found in urine [9]. Adverse drug events
or symptoms of bupropion intoxications, i.e., insomnia, vomiting, dry mouth or seizures,
can be attributed to bupropion and its metabolites [10]. It was observed that erythrohy-
drobupropion plasma levels significantly correlate with insomnia, while threohydrobupro-
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pion is assumed to be responsible for dry mouth [11]. Moreover, hydroxybupropion
induced seizures more potently than bupropion in rodent experiments [12] and immediate
release administration of bupropion was associated with a higher incidence of seizures
than a sustained release administration in humans [10,13,14]. All three metabolites are
further metabolized via glucuronidation by uridine 5′-diphospho-glucuronosyltransferase
(UGT) 2B7 [15].
According to the United States Food and Drug Administration (FDA), bupropion is
listed as a sensitive substrate of CYP2B6 in clinical drug–drug interaction studies (DDIs),
ref. [16] and it is subject to various CYP2B6 DDIs, when inducers or inhibitors of CYP2B6
are administered concomitantly [17,18]. For example, HIV patients that are on bupropion
medication exhibited a 57% decrease in bupropion AUC at the initiation of antiviral
therapy with ritonavir, an inducer of CYP2B6 [19,20]. Clopidogrel, an antiplatelet drug
and known CYP2B6 inhibitor, was reported to decrease hydroxybupropion AUC by 60%
after pretreatment with 75 mg clopidogrel [21]. Even short-term use of CYP2B6 perpetrator
drugs can seriously affect bupropion hydroxylation, as shown for the administration of
fluvoxamine and voriconazole shortly before bupropion administration that caused a 90%
reduction in the hydroxybupropion to bupropion AUC plasma ratio (AUCHBup/Bup) [22].
In addition to its CYP2B6 interaction potential, bupropion is also listed as a strong clinical
inhibitor of CYP2D6 [16]. However, the inhibitory effect is primarily attributed to its
metabolites hydroxybupropion, erythrohydrobupropion, and threohydrobupropion [23].
In addition to its DDI potential, bupropion is also subject to CYP2B6 drug–gene
interactions (DGIs). Polymorphisms in the CYP2B6 gene can result in rapid, normal, inter-
mediate, or poor metabolizer phenotypes. Important genetic variants of CYP2B6 include
CYP2B6*1, *4, *5, and *6 with frequencies of 49%, 4%, 12%, and 23% in European pop-
ulations, respectively [17,24]. It has been shown that hydroxybupropion plasma levels
and hydroxybupropion to bupropion plasma ratios are significantly altered in rapid or
poor metabolizers, with 153% higher or 31% lower hydroxybupropion to bupropion AUC
ratios compared to wildtype [17]. However, the clinical relevance for CYP2B6 polymorphic
patients is still unclear and dose adjustment guidelines have yet to be developed.
Considering the DDI, DGI and drug–drug–gene interaction (DDGI) potential, the com-
plex pharmacokinetics of bupropion should be thoroughly investigated. Here, physiologically
based pharmacokinetic modeling (PBPK) can be a valuable tool to grasp the high level
of complexity and implications of genetic polymorphisms and perpetrator drugs on the
pharmacokinetics of bupropion [25]. However, a robust bupropion PBPK model connected
to a strong DDGI CYP2B6 network has not been developed yet.
The aim of the presented work was the development of a PBPK model of bupro-
pion including its three most relevant metabolites for the prediction of CYP2B6 DDI,
DGI, and DDGI scenarios, and the qualification of this model using clinical data of CYP2B6
polymorphic individuals and DDI studies with different perpetrator drugs in the first
published CYP2B6 DDGI network. The final model is shared with the modeling and
drug development community in the Open Systems Pharmacology model repository
(www.open-systems-pharmacology.org, December 2020) [26]. A transparent and compre-
hensive documentation of model development and evaluation is provided in the Supple-
mentary Materials.
2. Materials and Methods
2.1. Software
The PBPK model was developed with the open-source modeling software PK-Sim®
and MoBi® (Open Systems Pharmacology Suite 9.1, released under the GPLv2 license
by the Open Systems Pharmacology community, www.open-systems-pharmacology.org
(accessed on 31 December 2020)) [26]. GetData Graph Digitizer 2.26.0.20 (© S. Fedorov) was
used to digitize published clinical study data according to best practices [27]. Model input
parameters were optimized by application of the Levenberg–Marquardt algorithm with
multiple starting values. Local sensitivity analyses were performed within PK-Sim®.
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Non-compartmental analyses, model performance measures, and plots were compiled in R
3.6.3 (The R Foundation for Statistical Computing, Vienna, Austria) with RStudio 1.2.5033
(RStudio PBC, Boston, MA, USA).
2.2. Clinical Data
Clinical studies of bupropion in single-and multiple-dose regimens were gathered and dig-
itized from the literature [27]. The collected profiles were divided into a training (n = 19) and a
test dataset (n = 48), used for model building and model evaluation, respectively [3,17–22,28–57].
Studies in the training dataset were selected to include metabolite concentration-time
profiles, a wide dosing range, and different oral formulations. To minimize bias, the distri-
bution of data on female and male populations was balanced as well. The whole dataset
is documented in the clinical study tables, with their respective clinical data shown in
semilogarithmic as well as linear plots in Sections 2–4 of the Supplementary Materials.
2.3. PBPK Model Building
Model building was started with an extensive literature search for physicochemical
properties and information regarding absorption, distribution, metabolism, and excretion
(ADME) processes of bupropion and its investigated metabolites.
Averaged demographic information about age, sex, ethnicity, body weight, and height
listed in clinical study reports was used to create virtual individuals. If data on demograph-
ics was missing, a virtual standard individual with default values was created. Details on
standard individuals are listed in Table S1.2 of the Supplementary Materials. Virtual popu-
lations of 500 individuals were created based on the demographic information provided in
the clinical study reports. If no data was available, a male European population with an
age distribution of 20–50 years was assumed.
Tissue distribution of enzymes and binding proteins used for the ADME processes
of bupropion and its metabolites was implemented according to the PK-Sim® expression
database [58]. Information on their expression is provided in Table S1.1 of the Supplemen-
tary Materials.
Tablet formulations with different bupropion release kinetics were simulated using a
Weibull model (Section 1.1 in the Supplementary Materials). The Weibull shape and Weibull
time parameters (50% dissolved) were derived, if available, from dissolution profiles
reported in the literature. Model parameters that either could not be sufficiently informed
from the literature or were involved in important QSAR model estimates of permeability
and distribution processes were optimized by fitting the model simultaneously to all
plasma concentration-time profiles of the training dataset.
2.4. PBPK Model Evaluation
PBPK model evaluation was performed using several methods. Model predictions of
plasma concentration-time profiles were graphically compared to observed profiles from
the respective clinical studies. Subsequently, predicted plasma concentrations from all
studies were plotted against their corresponding observed values in goodness-of-fit plots.
The model performance was further evaluated by comparison of predicted to observed area
under the plasma concentration-time curve (AUC) and maximum plasma concentration
(Cmax) values. AUC values (predicted as well as observed) were calculated from the
time of drug administration to the time of the last concentration measurement (AUClast).
If measured profiles were missing, predicted AUC was calculated as reported in the
corresponding study. As quantitative measures of the model performance, mean relative
deviation (MRD) of all predicted and observed plasma concentrations and geometric mean
fold error (GMFE) of all predicted and observed AUClast and Cmax values were calculated
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according to Equations (1) and (2). Predictions with MRD and GMFE values ≤ 2 were
considered successful model predictions.
MRD = 10x; x =
√√√√ ∑ki=1 (log 10ĉi− log10ci)2
k
(1)
where ci = the ith observed plasma concentration, ĉi = the corresponding predicted plasma
concentration, and k = the number of observed values.









where predicted PK parameteri = the ith predicted AUClast or Cmax value, observed PK
parameteri = the corresponding observed AUClast or Cmax value, and m = the number
of studies.
Local sensitivity of the AUC of bupropion, hydroxybupropion, erythrohydrobupro-
pion, and threohydrobupropion to single parameter changes was analyzed for bupropion
multiple dose administrations of the three different release formulations. Analyses in-
cluded parameters that were either optimized or assumed to have an impact on AUC.
A detailed description is provided in the Supplementary Materials Section 2.5.5.
2.5. DGI, DDI and DDGI Modeling
To model the effect of CYP2B6 genetic variants, difference in enzyme activity was ex-
pressed by variation of the Michaelis-Menten (KM) and catalytic rate constant (kcat) values
for CYP2B6*1/*1 (wildtype), CYP2B6*1|*4, CYP2B6*1|*6, CYP2B6*5|*5, and CYP2B6*6|*6
genotypes. Parameters that could not be informed from literature were optimized by fitting
the model to clinical data based on a population with the respective genotype. If no data on
genotype or phenotype of the investigated subjects was available, CYP2B6 wildtype was
assumed. If mean plasma concentration-time profiles of different genotypes were reported,
the most frequent one was used for model simulations.
To model the effect of DDIs, different interaction processes (competitive inhibition or
induction) were incorporated into the perpetrator PBPK model with the corresponding
in vitro interaction parameters values extracted from the literature. The different interaction
types are described in the Supplementary Materials Section 1.6. Previously published PBPK
models of the CYP2B6 perpetrator drugs rifampicin, voriconazole, and fluvoxamine were
used to simulate DDI scenarios with bupropion [59–61].
To predict the rifampicin-bupropion DDGIs in carriers of different CYP2B6 alleles,
inhibition and induction parameters for wildtype DDI simulations were assumed.
2.6. DGI, DDI and DDGI Model Evaluation
DGI, DDI, and DDGI model performance was evaluated by comparison of predicted
to observed plasma concentration-time profiles of bupropion (Bup) and its CYP2B6 metabo-
lite hydroxybupropion (HBup) after single administration and during concomitant ad-
ministration of CYP2B6 perpetrator drugs (rifampicin or fluvoxamine and voriconazole).
In addition, the metabolite–parent ratio HBup/Bup of the PK parameters AUC (AUClast or
AUCinf [AUC extrapolated to infinity]) and Cmax was calculated for predicted and observed
effect and control profiles according to Equation (3). HBup/Bup AUC and Cmax ratios
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where Bup PK = PK parameter of bupropion, and HBup PK = PK parameter of hydroxybupropion.
DGI, DDI or DDGI PKHBup/Bup =
PKHBup/Bup (DGI, DDI or DDGI)
PKHBup/Bup (reference)
(4)
where PKHBup/Bup = Hydroxybupropion-bupropion PK parameter ratio.
As a quantitative measure of DGI, DDI, and DDGI model performance, GMFE values
of the predicted and observed PKHbup/Bup values as well as PKHbup/Bup effect ratios were
calculated according to Equation (2).
3. Results
3.1. Model Building and Evaluation
A PBPK model for bupropion and its three metabolites, hydroxybupropion,
erythrohydrobupropion, and threohydrobupropion was developed. A total of 48 clin-
ical studies in which bupropion was administered in a wide dosing range (20–300 mg) as
immediate, sustained, and extended release tablets in single or multiple dose regimens
were used in the model development process. In total, all 48 studies included plasma
concentration-time profiles of bupropion, 40 of hydroxybupropion, and 17 of erythro- and
threohydrobupropion. Study details are listed in Table S2.1 of the Supplementary Materials.
For the extended release tablet formulation, Weibull parameters were calculated from
dissolution profiles from the literature according to Langenbucher et al. [62]. For additional
formulations, parameters were fitted to plasma concentration-time profiles of the training
dataset. Dissolution details are listed in Table S2.2 of the Supplementary Materials.
Figure 1a illustrates the basic structure of the developed whole-body PBPK model and
implemented DGI and DDI processes. Figure 1b summarizes the implemented metabolism
of bupropion via CYP2B6 to hydroxybupropion and via 11β-HSD to erythro- and thre-
ohydrobupropion. Moreover, CYP2B6 metabolism is influenced by genetic variants and
perpetrator drugs, such as the CYP2B6 inducer and inhibitor rifampicin [63,64] and the
CYP2B6 inhibitor voriconazole [65]. Bupropion metabolism via CYP2C19 was modeled to
reflect minor metabolic pathways of bupropion covered by other CYPs. Since binding to
therapeutic targets might influence the PK of bupropion, binding to a surrogate protein rep-
resenting various neurotransmitter transporters was implemented. Furthermore, the model
applied glucuronidation of the three metabolites via UGT2B7. UGT2B7 and CYP2C19
metabolism were also considered in DDI predictions, as fluvoxamine and voriconazole
inhibit CYP2C19 [65,66] and rifampicin induces CYP2C19. Moreover, both compounds
induce and inhibit UGT2B7 [64,67]. In summary, the simulated effects include: (i) CYP2B6
polymorphisms; (ii) induction of CYP2B6, CYP2C19 and UGT2B7, and inhibition of CYP2B6
and UGT2B7 by rifampicin; and (iii) inhibition of CYP2C19 by fluvoxamine as well as
inhibition of CYP2B6 and CYP2C19 by voriconazole.
Tables 1 and 2 provide an overview of the drug-dependent model parameters as well
as details on the implemented metabolic processes. A description of all implemented
processes and formulations with their respective model parameters is listed in the drug-
dependent parameter table in the Supplementary Materials.
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Figure 1. Modeling overview of the CYP2B6 DDGI Network. A whole-body PBPK model was augmented for the simulation
of CYP2B6 drug–drug, drug–gene, and drug–drug–gene interactions (a). The model describes bupropion’s metabolism
via CYP2B6, CYP2C19, and 11β-HSD (b). Its metabolites hydroxybupropion, erythro- and threohydrobupropion are
transformed via UGT2B7. Binding to an unspecific binding protein, representing bupropion’s pharmacological targets,
was implemented. Several effects on the bupropion PK were modeled, i.e., effects of genetic polymorphisms on CYP2B6;
induction of CYP2C19 by rifampicin; induction and inhibition of CYP2B6 and UGT2B7 by rifampicin; inhibition of CYP2C19
by fluvoxamine; and inhibition of CYP2B6 and CYP2C19 by voriconazole. Drawings by Servier, licensed under CC BY
3.0 [68]. 11β-HSD: 11β-hydroxysteroid-dehydrogenase, CYP2B6: cytochrome P450 2B6, CYP2C19: cytochrome P450 2C19,
UGT2B7: uridine 5′-diphospho-glucuronosyltransferase 2B7.
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Table 1. Drug-dependent parameters of the bupropion PBPK model.
Parameter Value Unit Source Literature Reference Description
MW 239.74 g/mol lit. 239.74 [69] Molecular Weight
pKa 8.75 - lit. 8.75 [70] Acid dissociation constant
Solubility (pH = 7.40) 365.56 mg/mL lit. 365.56 [71] Solubility
log P 2.57 - fit. 3.27 [69] Lipophilicity
fu 16.00 % lit. 16.00 [23] Fraction unbound
Intestinal perm. 2.76 × 10−5 cm/min fit. - - Transcellular intestinal permeability
Partition coefficients Diverse - calc. Berez. [72] Cell to plasma partitioning
Cellular Perm. - - fit. PK-Sim [73] Permeability into the cellular space
GFR fraction 1.00 - asm. - Filtered drug in urine
EHC cont. fraction 1.00 - asm. - Bile fraction continuously released
KM CYP2B6*1→ HBup ‡ 25.80 µmol/L lit. ‡ 25.80 [74] Michaelis-Menten constant
kcat CYP2B6*1→ HBup * 10.87 1/min fit. - - Catalytic rate constant
KM CYP2B6*6→ HBup ‡ 61.26 µmol/L lit. ‡ 61.26 [74] Michaelis-Menten constant
kcat CYP2B6*6→ HBup * 9.52 1/min fit. - - Catalytic rate constant
KM CYP2B6*4→ HBup 12.70 µmol/L lit. 12.70 [75] Michaelis-Menten constant
kcat CYP2B6*4→ HBup a 18.13 1/min lit. * 18.13 [75] Catalytic rate constant
KM 11β-HSD→ EBup 39.10 µmol/L lit. 39.10 [76] Michaelis-Menten constant
kcat 11β-HSD→ EBup 2.15 1/min fit. - - Catalytic rate constant
KM 11β-HSD→ TBup 39.10 µmol/L lit. 39.10 [76] Michaelis-Menten constant
kcat 11β-HSD→ TBup 8.18 1/min fit. - - Catalytic rate constant
KM CYP2C19 8.30 µmol/L lit. 8.30 [77] Michaelis-Menten constant
kcat CYP2C19 2.59 1/min fit. - - Catalytic rate constant
KD Binding partner 0.44 µmol/L fit. b 0.35–0.60 [78–80] Dissociation constant for binding
koff Binding partner 0.05 1/min fit. - - Dissociation rate constant for binding
‡ in vitro values corrected for binding in the assay using fraction unbound to microsomal protein measurements from the same study, * half of the optimized parameter, a calculated mean of enantiomer selective
degradation, b also includes inhibition constant values (Ki), 11β-HSD: 11β-hydroxysteroid-dehydrogenase, asm.: assumed, Berez.: Berezhkovskiy calculation method, calc.: calculated, cont.: continuous, CYP2B6:
cytochrome P450 2B6, CYP2C19: cytochrome P450 2C19, EBup: erythrohydrobupropion, EHC: enterohepatic circulation, fit.: optimized parameter, GFR: glomerular filtration rate, HBup: hydroxybupropion, lit.:
literature, perm.: permeability, PK-Sim: PK-Sim® standard calculation method, TBup: threohydrobupropion.
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Table 2. Drug-dependent parameters of the hydroxybupropion, erythrohydrobupropion and threohydrobupropion PBPK models.
Parameter Value Unit Source Literature Reference Value Unit Source Literature Reference Description
Hydroxybupropion Erythro-and Threohydrobupropion
MW 255.74 g/mol lit. 255.74 [81] 241.76 g/mol lit. 241.76 [82] Molecular Weight
pKa 7.65 - lit. 7.65 [81] 9.71 - lit. 9.71 [82] Acid dissociationconstant
Solubility (pH = 7.40) 0.91 mg/mL lit. 0.91 [81] 82.98 mg/mL lit. 82.98 [82] Solubility
log P 1.90 - fit. 2.20 [83] 1.89 - fit. 2.98 [82] Lipophilicity
fu 23.00 % lit. 23.00 [23] 58.00 % lit. 58.00 [23] Fraction unbound
Partition coefficients Diverse - calc. Berez. [72] Diverse - calc. Berez. [72] Cell to plasmapartitioning
Cellular Perm. - - fit. Ch.d.S. [84] - - fit. Ch.d.S. [84] Permeability into thecellular space
GFR fraction 1.00 - asm. - - 1.00 - asm. - - Filtered drug in urine
EHC cont. fraction 1.00 - asm. - - 1.00 - asm. - - Bile fractioncontinuously released







kcat UGT2B7 1.09 1/min fit. - - (E) 0.63(T) 0.10 1/min fit. - - Catalytic rate constant
‡ in vitro values corrected for binding in the assay using fraction unbound to microsomal protein measurements from the same study, asm.: assumed, Berez.: Berezhkovskiy calculation method, calc.: calculated,
Ch.d.S.: Charge dependent Schmitt calculation method, cont.: continuous, E: erythrohydrobupropion, EHC: enterohepatic circulation, GFR: glomerular filtration rate, fit.: optimized parameter, lit.: literature,
perm.: permeability, T: threohydrobupropion, UGT2B7: uridine 5′-diphospho-glucuronosyltransferase 2B7.
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Figure 2a–i presents simulations of bupropion administration as immediate,
sustained, and extended release tablets. The bupropion PBPK model accurately de-
scribed and predicted plasma concentration-time profiles of bupropion and its metabo-
lites after single and multiple dose administrations for the three different formulations.
Predicted concentration-time profiles of all 48 clinical studies compared to observed data
are provided on linear and semi-logarithmic scale in Figures S2.4.1–S2.4.14 in the Sup-
plementary Materials. All simulated plasma profiles were in good agreement with their
respective observed data.
Figure 2. Predicted plasma concentration-time profiles of selected clinical studies from test and training datasets for
bupropion, hydroxybupropion, erythro- and threohydrobupropion after application of single and multiple oral tablets with
immediate release (a–c), sustained release (d–f) and extended release (g–i) kinetics compared to observed data [3,28,32,51,54].
The geometric means of the population predictions (n = 500) are shown as solid lines and corresponding observed data
as dots (arithmetic mean ± standard deviation, if available). The shaded areas indicate the geometric standard deviation.
Detailed information on study protocols is provided in Table S2.1 of the Supplementary Materials. ER: extended release,
IR: immediate release, m.d.: multiple dose, n: number of participants, s.d.: single dose, SR: sustained release, ta: training
dataset, te: test dataset.
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Model performance is demonstrated in Figure 3 as comparisons of predicted to ob-
served AUClast (a) and Cmax values (b). Both training and test data were well predicted
for all four compounds. In addition, Table 3 provides MRDs of plasma concentration-
time profiles and GMFEs of AUClast and Cmax for the four compounds. With 119/124
of the predicted AUClast and 121/124 of the predicted Cmax values within the 2-fold ac-
ceptance limits, total GMFEs of 1.31 (range 0.43–3.06) for predicted AUClast values and
1.29 (range 0.55–2.87) for Cmax values further confirmed an adequate model performance.
Individual MRD and GMFE values for all plasma profiles are listed in Tables S2.3 and S2.4
in the Supplementary Materials.
Figure 3. Goodness-of-fit plots of PK parameters for bupropion and metabolites. Predicted AUC
of the training (a) and test dataset (b) as well as Cmax values of the training (c) and test dataset
(d) compared to observed values. The solid line marks the line of identity, dotted lines indicate
1.25-fold, and dashed lines indicate 2-fold deviation. AUC: area under the plasma concentration-
time curve from the time of drug administration to the time of the last concentration measurement,
Cmax: maximum plasma concentration.
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Table 3. Summary of quantitative measures of model performance for bupropion and its metabolites,
separated by training and test dataset.
Mean MRD Mean GMFEAUC Mean GMFECmax
training test training test training test
Bupropion 1.62 1.90 1.20 1.42 1.20 1.41
Hydroxybupropion 1.16 1.30 1.14 1.34 1.10 1.32
Erythrohydrobupropion 1.48 1.38 1.25 1.46 1.26 1.38
Threohydrobupropion 1.36 1.21 1.36 1.23 1.17 1.30
Overall 1.51 1.31 1.29
Profiles with measure ≤ 2 103/124 119/124 121/124
Range 1.01–6.21 0.43–3.06 0.55–2.87
AUC: area under the plasma concentration-time curve from the time of drug administration to the time of the
last concentration measurement, Cmax: maximum plasma concentration, GMFE: geometric mean fold error,
MRD: mean relative deviation.
Sensitivity analysis of a 14-day multiple dose simulation of either 100 mg immediate
release three times daily, 150 mg sustained release twice daily, or 300 mg extended release
once daily, revealed that regardless of the bupropion formulation, the highest impact on
bupropion AUC can be attributed to the fraction unbound of bupropion, a fixed literature
value. Of the optimized parameters, the most impactful parameter was CYP2B6 kcat
for immediate and sustained release formulations. For the extended release formulation,
AUC was more sensitive to bupropion lipophilicity than to CYP2B6 kcat. A detailed
assessment of model sensitivity is provided in Section 2.5.5 of the Supplementary Materials.
3.2. DGI Modeling and Evaluation
The developed model was extended to describe effects of polymorphism in the
CYP2B6 gene on CYP2B6 activity and interaction with CYP2B6 perpetrator drugs. Most pub-
lished studies only reported mean profiles of populations, often exhibiting multiple differ-
ent genotypes, or only the respective AUC or HBup/Bup ratio of plasma AUC or single
concentrations at specific time points after administration. However, plasma concentration-
time profiles of four genetic variants could be gathered from the literature. These included:
CYP2B6*1 (or wildtype), CYP2B6*4, CYP2B6*5, and CYP2B6*6. Three studies reporting
profiles of bupropion and hydroxybupropion were used for development of DGI predic-
tions. Michaelis Menten constants (KM) were obtained from the literature and corrected
for binding in the microsomal assay, if necessary. The rate constant kcat was optimized for
the CYP2B6*6 haplotype. Table 1 provides bupropion KM and kcat values for the imple-
mented CYP2B6 alleles. Prediction of CYP2B6*4 heterozygous expression was simulated by
splitting the implemented CYP2B6-mediated pathway in two clearance processes. In vitro
parameters representing the CYP2B6 partition not produced by the CYP2B6*4 allele were
assumed to be equal to parameters for homozygous expression of the respective allele
(i.e., CYP2B6*1/*1 or CYP2B6*6/*6). For example, the CYP2B6*1 allele was simulated with
a KM value of 25.80 µmol/l from the literature and half of the optimized CYP2B6*1|*1
kcat value of 21.74 1/min. Figure 4 demonstrates the performance of the bupropion
DGI model with Figure 4a–c illustrating model-based simulations of 150 mg bupropion
as an immediate release tablet alongside their respective observed profiles of three dif-
ferent polymorphisms in comparison to CYP2B6*1|*1 (wildtype). The effect of DGIs,
especially on hydroxybupropion plasma levels, was well described for rapid (CYP2B6*1|*4),
normal (CYP2B6*1|*1 or wildtype), intermediate (CYP2B6*1|*6) and poor metaboliz-
ers (CYP2B6*6|*6). Plots documenting the model performance for all modeled bupro-
pion DGIs are provided in Figures S3.4.1 and S3.4.2 of the Supplementary Materials.
Figure 4d–e shows predicted compared to observed DGI HBup/Bup ratios calculated
for AUC (d) and Cmax (e). Predicted DGI HBup/Bup ratios were in good agreement
with observed ratios, with 20/20 of DGI AUCHBup/Bup and 8/8 of DGI Cmax HBup/Bup
values within the 2-fold acceptance limits and 18/20 of DGI AUCHBup/Bup and 7/8 of DGI
Cmax HBup/Bup values within the prediction success limits suggested by Guest et al. with
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1.25-fold variability [85]. Predicted and observed DGI AUCHBup/Bup ratios showed an
overall GMFE of 1.25 (range 0.64–1.77) and DGI Cmax HBup/Bup of 1.35 (range 0.41–1.29).
Tables S3.3 and S3.4 of the Supplementary Materials list all calculated MRD and GMFE val-
ues of predicted and observed plasma concentration-time profiles and the corresponding
AUC and Cmax values along with the DGI HBup/Bup ratios.
Figure 4. Bupropion CYP2B6 DGI model evaluation. Predicted compared to observed plasma concentration-time profiles
are illustrated for CYP2B6*1/*4 (a), CYP2B6*1/*6 (b) and CYP2B6*6/*6 (c) genotypes [17] in comparison to the CYP2B6*1/*1
genotype (wildtype, n = 21). The effects of respective genetic variants of CYP2B6 are shown in orange and blue for
bupropion and hydroxybupropion, respectively; the corresponding profiles of the CYP2B6*1/*1 genotype are shown in
red and green for bupropion and hydroxybupropion, respectively. The solid line illustrates the geometric mean of the
population predictions (n = 500) and the shaded area the geometric standard deviation. Predicted compared to observed
DGI effect ratios are shown for hydroxybupropion–bupropion ratios of AUC (d) and Cmax (e) with different colors indicating
the genotypes and different shapes the respective studies [17,35,40,44]. The straight solid line marks the line of identity,
the curved solid lines show the prediction acceptance limits proposed by Guest et al. including 1.25-fold variability [85].
Dotted lines indicate 1.25-fold and dashed lines indicate 2-fold deviation. Details on the study protocols and DGI ratios are
provided in the Supplementary Materials. AUC: area under the plasma concentration-time curve, Cmax: maximum plasma
concentration, DGI: drug–gene interaction, HBup/Bup: hydroxybupropion–bupropion ratio, IM: intermediate metabolizer,
IR: immediate release, PM: poor metabolize, RM: rapid metabolizer, s.d.: single dose.
3.3. Bupropion DDI Modeling and Evaluation
The bupropion DDI model was established and evaluated using a total of five clinical
DDI studies with the perpetrator drugs fluvoxamine together with voriconazole (one study)
and rifampicin (four studies). Details on the previously developed PBPK models for
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rifampicin [60], fluvoxamine [61], and voriconazole [59] are listed in the parameter tables
in Section 4 of the Supplementary Materials.
The rifampicin-bupropion DDI was predicted as an induction of CYP2B6, CYP2C19,
and UGT2B7 with interaction parameters obtained from the literature [63,64,67].
Additionally, competitive inhibition of CYP2B6 and UGT2B7 by rifampicin was included
as well [86,87].
The fluvoxamine-voriconazole-bupropion DDI was predicted as competitive inhi-
bition of CYP2B6 and CYP2C19 metabolism by voriconazole and competitive inhibition
of CYP2C19 by fluvoxamine. Literature CYP2C19 Ki values were used for both fluvox-
amine and voriconazole [65,66]. CYP2B6 Ki of voriconazole was adjusted via parameter
optimization.
Figure 5a–c illustrates predicted plasma concentration-time profiles before and dur-
ing DDI scenarios in comparison to the corresponding observed data from clinical DDI
studies. Induction by rifampicin and inhibition via fluvoxamine and voriconazole are
shown for bupropion and hydroxybupropion plasma levels on linear scale for three repre-
sentative studies (two for rifampicin DDIs with different bupropion release formulations
and one for fluvoxamine and voriconazole). In Section 4 of the Supplementary Materials,
predicted compared to observed profiles of all investigated rifampicin–bupropion DDIs
are presented. In the DDI studies, 600 mg rifampicin were administered daily with
150 mg bupropion given once either as immediate release (Figure 5a) or sustained re-
lease tablets (shown in Figure 5b, Figure 6 and in Section 4 of the Supplementary Materials).
Plasma concentration-time profiles during CYP2B6 inhibition were only provided in one
DDI study with a single dose of bupropion as a cocktail capsule [22]. For the fluvoxamine–
voriconazole–bupropion DDI scenario, fluvoxamine and voriconazole were administered
concomitantly, 2 h before the bupropion cocktail capsule. Further details on regimens
and population characteristics of the DDI studies are listed in Tables S4.4 and S4.5 of the
Supplementary Materials.
HBup/Bup ratios were calculated via Equations (4) and (5) for AUC and Cmax
values and are depicted in Figure 5d–e. Here, 12/13 DDI AUCHBup/Bup and 6/6 DDI
Cmax HBup/Bup values were within the limits proposed by Guest et al. assuming 1.25-fold
variability [85] with overall GMFE values of 1.23 (range 0.74–1.73) for DDI AUCHBup/Bup
and 1.46 (range 0.56–1.44) for DDI Cmax HBup/Bup. Calculated MRD and GMFE values of
all predicted DDI studies are listed in Tables S4.6 and S4.7 of the Supplementary Materials.
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Figure 5. Victim drug plasma concentrations and DDI HBup/Bup ratios for AUC and Cmax of the modeled bupropion DDIs.
Predicted compared to observed plasma concentration-time profiles of bupropion and hydroxybupropion are shown for
interactions with rifampicin (a,b) as well as fluvoxamine and voriconazole (c). The profiles during administration of CYP2B6
perpetrator drugs are shown in orange and blue for bupropion and hydroxybupropion, respectively, and the corresponding
profiles without DDI are shown in red and green for bupropion and hydroxybupropion, respectively. The solid line
illustrates the geometric mean of the population predictions (n = 500) and the shaded area the geometric standard deviation.
Predicted compared to observed effect ratio plots for the hydroxybupropion–bupropion ratios of AUC (d) and Cmax (e) show
data of four CYP2B6 inducer and one CYP2B6 inhibitor studies. Different shapes indicate the perpetrators and different
colors the respective studies [19,22,35,44]. The straight solid line marks the line of identity; the curved solid lines show the
prediction acceptance limits proposed by Guest et al. including 1.25-fold variability [85]. Dotted lines indicate 1.25-fold
and dashed lines indicate 2-fold deviation. Details on the study protocols and the values of all DDI ratios are provided in
the Supplementary Materials. AUC: area under the plasma concentration-time curve, Cap: capsule (Geneva Capsule [22]),
Cmax: maximum plasma concentration, DDI: drug-drug interaction, Fluvo/Vori: fluvoxamine and voriconazole, HBup/Bup:
hydroxybupropion–bupropion ratio, Ind: inducer, Inh: inhibitor, IR: immediate release, Rifa: rifampicin, s.d.: single dose,
SR: sustained release.
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Figure 6. Rifampicin–bupropion CYP2B6 DDGI. Predicted compared to observed plasma concentration-time profiles
are illustrated for the CYP2B6 bupropion DGI (CYP2B6*1|*6 compared to CYP2B6*1|*1) (a), for rifampicin–bupropion
DDI in individuals with the CYP2B6*1|*1 genotype (b) and for the rifampicin–bupropion DDGI for individuals with
the CYP2B6*1|*6 genotype compared to carriers of the CYP2B6*1|*1 genotype (c). The predicted and observed plasma
concentrations under the combined effects of CYP2B6 genetic polymorphism and perpetrators are shown in orange and blue,
respectively, while the control is shown in red and green. The solid line illustrates the geometric mean of the population
predictions (n = 500) and the shaded area the geometric standard deviation. Predicted compared to observed effect ratio plot
for the hydroxybupropion–bupropion ratio of AUC values are shown for six different genotypes after rifampicin induction
(d). Different colors indicate the genotypes and different shapes the respective studies ([35,44]). The straight solid line
marks the line of identity, the curved solid lines show the prediction acceptance limits proposed by Guest et al. including
a 1.25-fold variability [85]. Dotted lines indicate 1.25-fold and dashed lines indicate 2-fold deviation. Predicted effects of
rifampicin-bupropion DDGIs on the hydroxybupropion-bupropion AUC ratios were compared to CYP2B6*1|*1 without
co-administration of rifampicin (e). Details on study protocols and DDGI ratios are provided in the Supplementary
Materials. AUC area under the plasma concentration-time curve, DGI: drug–gene interaction, DDI: drug–drug interaction,
DDGI: drug drug gene interaction, HBup/Bup: hydroxybupropion–bupropion ratio, Ind: inducer, po: oral, s.d.: single dose,
SR: sustained release.
3.4. Bupropion DDGI Modeling and Evaluation
DDGIs, combinations of DGIs and DDIs, were predicted for the polymorphisms
CYP2B6*1, CYP2B6*4, CYP2B6*5, and CYP2B6*6 for bupropion intake in DDI scenarios
with concomitant rifampicin administration. Rifampicin was administered in multiple oral
doses of 600 mg (daily) before a single oral dose of 150 mg bupropion (sustained release)
was administered [35,67]. One DDGI study reported plasma concentration-time profiles
of bupropion and hydroxybupropion for CYP2B6*1|*1 and CYP2B6*1|*6 either with or
without rifampicin. Figure 6a–c shows predicted compared to observed profiles for a DGI
in CYP2B6*6 heterozygous subjects (a), a DDI with rifampicin in CYP2B6 wildtype subjects
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(b), and a DDGI with rifampicin in CYP2B6*6 heterozygous subjects (c) compared to CYP2B6
wildtype subjects receiving bupropion solely. Furthermore, HBup/Bup ratios of AUCinf
after rifampicin induction were reported for several CYP2B6 polymorphic individuals [44].
Figure 6d illustrates predicted compared to observed DDGI AUCHBup/Bup values for
several genetic variants of CYP2B6.
Figure 6e shows predicted AUCHBup/Bup values for all possible allele combinations of
the modeled CYP2B6 variants with or without rifampicin interaction. HBup/Bup ratios
were decreased in carriers of the variant CYP2B6*6 allele. A homozygous CYP2B6*6 ex-
pression with inducer was predicted to be lower in CYP2B6 activity than wildtype CYP2B6
without inducer resulting in a ~15% decrease in AUCHBup/Bup. CYP2B6*5|*6 individuals
were predicted to exhibit AUCHBup/Bup ratios similar to wildtype individuals, with or
without inducer. The highest AUCHBup/Bup was simulated for homozygous expression of
the gene variant CYP2B6*4 after rifampicin intake. However, it should be noted that for pre-
dictions of the genotypes CYP2B6*4|*4 and CYP2B6*5|*6, no observed data for validation
were available. In summary, DDGI predictions showed overall DDGI AUCHBup/Bup GMFE
values of 1.27 (range 0.85–1.60) with 7/7 of the predicted DDGI AUCHBup/Bup within the
acceptance limits of Guest et al., assuming 1.25-fold variability [85].
4. Discussion
In the presented work, a whole-body PBPK model of bupropion and its metabolites
hydroxybupropion, threohydrobupropion and erythrohydrobupropion was built and
evaluated to predict drug plasma concentrations over a wide dosing range (20–300 mg)
for three different oral formulations. Furthermore, the model was extended to describe
the effects of CYP2B6 DGIs, DDIs, and rifampicin-bupropion CYP2B6 DDGIs on the PK of
bupropion and its metabolites.
So far, only one other bupropion PBPK model has been published yet [88].
Despite demonstrating reasonable performance, in comparison to the presented work,
the model did not incorporate a similarly large amount of data for building and evaluation
and did not reflect the effects of different genetic alterations of CYP2B6. These shortcom-
ings, which we consider as necessary elements to qualify the bupropion PBPK model as a
part of the CYP2B6 network, were addressed in our model.
Bupropion is predominantly metabolized to hydroxybupropion in the liver and, to some
extent, also in the gut [10]. Even though CYP2B6 hydroxylation plays a major role in the
metabolism of bupropion, the implementation of CYP2C19 as minor metabolic pathway was
important to sufficiently describe the data including DDIs and DGIs [17,77]. In addition to
CYP2B6 and CYP2C19 metabolism, carbonyl reductases transform bupropion to erythro-
hydrobupropion and threohydrobupropion [10]. In the presented model, the metabolic
pathway along several carbonyl reductases was reduced to the rate-limiting enzymatic
step via 11β-HSD for the formation of erythrohydrobupropion and threohydrobupropion.
Here, the respective KM values for all implemented enzymes could be informed from the lit-
erature. After a single dose of 150 mg bupropion, the bupropion fractions metabolized were
predicted as 58%, 28%, and 13% via CYP2B6, 11β-HSD, and CYP2C19, respectively (Figure S2.1.1
of the Supplementary Materials). Furthermore, the model predicts an extensive metabolism
of bupropion (99%) after complete absorption with small fractions excreted unchanged to
urine and feces (~1%), which is consistent with the literature [9]. Reported bupropion frac-
tions metabolized varied with measurements from in vitro clearance data of 56% or 12% for
hydroxybupropion formation and 40% or 68% for threohydrobupropion formation [8,89],
which are in reasonable agreement with predicted values.
Bupropion shows affinity to a variety of therapeutic targets, such as numerous acetyl-
choline receptors and dopamine and noradrenaline reuptake transporters [10]. Target bind-
ing was incorporated into our model as it improved the description of the concentration-
time profiles. To simplify the complex binding of bupropion to several targets, only binding
to the noradrenaline reuptake transporter was implemented, as it covers the expression
in all relevant organs, such as brain or gastro-intestinal tract, where noradrenaline and
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dopamine reuptake transporters, as well as nicotinic acetylcholine receptors are expected.
The applied KD value is in good agreement with literature values describing binding or
inhibition of the different relevant targets [78–80].
The bupropion metabolism is especially sensitive to genetic polymorphisms in CYP2B6 [17].
Unfortunately, documentation on genetic polymorphisms of participants was poor in most
clinical studies. Either mean profiles of mixed populations were presented or no genotype
information was reported. Nevertheless, gene variants CYP2B6*1, *4, *5, and *6 were
included in our model and described the available plasma concentration-time profiles
of bupropion and hydroxybupropion sufficiently well. Dose adjustment guidelines for
genetic polymorphisms have not been implemented yet. However, as hydroxybupropion
might play an important role in the occurrence and onset of seizures after rapid bupropion
absorption [10,12–14], the presented model could support a rational individualized CYP2B6
polymorphism-guided dose selection.
The presented DDI network includes interactions via CYP2B6, CYP2C19, and UGT2B7.
The rifampicin–bupropion DDI covers the induction of CYP2B6, CYP2C19, and UGT2B7,
with simultaneous competitive inhibition of CYP2B6 and UGT2B7. All rifampicin–bupropion
interaction parameters were derived from the literature [45–48]. However, inhibition is
relatively weak with inhibition constants (Ki) of 118.50 µmol/L and 554.87 µmol/L for
CYP2B6 and UGT2B7 [86,87] and presumably negligible; especially after multiple dose
applications of rifampicin. For single dose administrations, rifampicin’s inhibitory activity
on bupropion could not be evaluated, due to a lack of clinical bupropion DDI data.
Voriconazole is a known CYP2B6 inhibitor that displayed interactions with bupropion
and efavirenz [74]. The reported Ki value of voriconazole was not strong enough to fully
describe the observed in vivo effects. This seems reasonable, since the metabolite voricona-
zole N-oxide is also responsible for the inhibitory effect on CYP2B6 [90], but was not
implemented in the published PBPK model [59]. Moreover, a polymorphism-dependent
CYP2B6 inhibition of voriconazole was previously described for efavirenz hydroxylation,
where lower Ki values were reported for CYP2B6*6 than for CYP2B6*1 [74]. In the DDI
study conducted by Bosilkovska et al. [22], six of 10 subjects exhibited a CYP2B6*6 poly-
morphism, which could potentially explain a deviation in prediction. Due to the lack of
relevant clinical data, the Ki value of voriconazole for CYP2B6 had to be optimized and
could not be validated yet. Hence, further in vitro studies are needed to optimize and
evaluate the voriconazole DDI. Inhibition of CYP2C19 was implemented, as fluvoxam-
ine and voriconazole are listed as strong and weak inhibitors for CYP2C19 by the FDA,
respectively [16]. As bupropion is also a known CYP2D6 inhibitor, we assumed that
the inhibitory effect on CYP2D6-mediated fluvoxamine metabolism is negligibly small,
as fluvoxamine is given 2 h prior to bupropion administration, and as bupropion’s strong
CYP2D6 inhibition potential is predominately attributed to its metabolites and a CYP2D6
downregulation after long-term bupropion intake [91].
The model correctly predicted DDGI plasma profiles of bupropion co-administered
with rifampicin in CYP2B6*6 heterozygous subjects. Furthermore, DDGI model perfor-
mance was successfully evaluated by comparison of predicted and reported HBup/Bup
AUC ratios. Subsequently, potential DDGIs were simulated for combinations of the ge-
netic CYP2B6 variants CYP2B6*1, CYP2B6*4, CYP2B6*5, and CYP2B6*6. The simulated
scenarios illustrate the models’ potential to investigate the effect of DDGIs on bupropion
and hydroxybupropion plasma levels. Whether the simulated DDGI combinations lead
to the predicted changes in HBup/Bup ratios, especially the profound increase in rapid
metabolizers receiving the CYP2B6 inducer rifampicin, should be carefully evaluated in
clinical studies. Moreover, pharmacological implications of bupropion intake, with or
without perpetrator, in CYP2B6 polymorphic patients, are still unclear. While clinical
efficacy or tolerability can be correlated to plasma levels of bupropion or its metabolites,
guidelines regarding bupropion dosing have yet to be established. Our presented model
demonstrated its flexibility in simulations of various DDGI scenarios and can be applied to
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develop rational dosing recommendations for bupropion drug labeling or clinical study
design.
5. Conclusions
A comprehensive parent-metabolite PBPK model of bupropion including whole-body
PBPK models of bupropion and the metabolites hydroxybupropion, erythrohydrobupro-
pion, and threohydrobupropion was developed. Bupropion pharmacokinetics were thor-
oughly described for tablets with different release formulations in single and multiple dose
regimens. The established CYP2B6 network incorporates reliable prediction of DGIs with
several polymorphisms, DDIs and DDGIs as combinations of DGIs and DDIs. A transparent
and detailed documentation of the model development and performance further under-
lines the model quality. The final PBPK model files are freely available in the Open Systems
Pharmacology repository (www.open-systems-pharmacology.org, December 2020) [26] to
assist the development of bupropion dosing guidelines and to support DDI studies in drug
discovery and development.
Supplementary Materials: The following are available at https://www.mdpi.com/1999-4923/13/3
/331/s1, Electronic Supplementary Materials: A comprehensive reference manual, providing docu-
mentation of the complete model performance assessment.
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